Understanding and treating vein graft atherosclerosis

Area of Science:

• Cardiovascular Surgery
• Vascular Biology
• Medical Therapeutics

Background:

• Coronary artery bypass grafting (CABG) using vein grafts is a common treatment for coronary artery disease.
• Vein graft atherosclerosis, a complication occurring around 10 years post-surgery, necessitates reoperation in some patients.
• Understanding the pathophysiology of vein graft atherosclerosis is crucial for developing effective treatments.

Purpose of the Study:

• To review the current knowledge on the pathophysiology of vein graft atherosclerosis.
• To summarize promising new therapeutic strategies for vein graft atherosclerosis.
• To explore the role of genomics in identifying risk factors and mechanistic insights.

Main Methods:

• Comprehensive literature review of epidemiology, histology, and cell/molecular pathophysiology.
• Analysis of studies investigating factors like trauma, lipids, and cellular processes (e.g., apoptosis).
• Evaluation of therapies tested in animal models and human clinical trials.

Main Results:

• Vein graft atherosclerosis development differs from arterial atherosclerosis.
• Key factors implicated include trauma, lipids, vasoactive mediators, smooth muscle cell proliferation and apoptosis, adhesion molecules, and proteases.
• Therapies targeting these factors have shown promise in preclinical and clinical studies.

Conclusions:

• Promising new therapies for vein graft atherosclerosis have been developed.
• Genomic approaches will further elucidate risk factors and mechanisms.
• Arterial grafts and myocardial revascularization techniques may offer superior long-term alternatives to vein grafts.